Participants in the pivotal SURMOUNT-1 trial who took the highest dose of tirzepatide lost an average of 22.5 percent of their body weight over 72 weeks, the largest weight loss recorded in an FDA trial for a non-surgical obesity treatment at the time. That is why Zepbound weight loss results have reshaped how clinicians and patients think about medical obesity care. Zepbound is the brand name for tirzepatide approved specifically for chronic weight management in adults, and its combination of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activity represents a mechanism in the weight-loss drug class. Importantly, Zepbound is a prescription medical treatment for a chronic disease, not a cosmetic shortcut. For the broader context of medical weight loss, see our wellness guide. This article is general information, not medical advice.
Important Safety Information: Boxed Warning
Zepbound carries the U.S. Food and Drug Administration’s most serious warning, a boxed warning, shared by the GLP-1/GIP drug class. In animal studies, tirzepatide caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether tirzepatide causes these tumors in humans. Because of this risk, Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
According to the FDA and MedlinePlus, you should tell your prescriber right away if you develop a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath, as these can be signs of a thyroid tumor. This safety information is not a substitute for the full prescribing information; review it with your clinician before starting treatment.
How Zepbound Works in the Body
Zepbound contains tirzepatide, a once-weekly injectable that activates two different gut hormone receptors simultaneously: GIP and GLP-1. These hormones are released naturally when you eat, and they signal your brain to reduce appetite, slow gastric emptying, and improve the body’s insulin response to food. By amplifying both signals, tirzepatide produces strong appetite suppression and, in trials, greater average weight loss than single-agonist GLP-1 drugs.
The dual mechanism matters clinically. GLP-1 alone, as in Wegovy, produces weight loss primarily through appetite reduction. Adding GIP activity contributes additional metabolic effects that researchers believe may enhance energy expenditure and improve fat handling. The full mechanistic picture is still being studied, but the trial data show consistently greater average weight loss with tirzepatide than semaglutide. Compare mechanisms in our Wegovy vs Mounjaro article.
What the Trial Data Actually Shows
The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity, or overweight with at least one weight-related comorbidity, but without type 2 diabetes. Over 72 weeks, participants randomized to tirzepatide lost an average of 15 percent of body weight on the lower dose studied and up to about 22.5 percent on the highest dose. Placebo participants lost just 2.4 percent.
SURMOUNT-2 extended the evidence to adults with both obesity and type 2 diabetes, showing average weight loss in the roughly 13 to 15 percent range – still robust though generally lower than in people without diabetes. More recently, the SURMOUNT-5 head-to-head trial against semaglutide showed tirzepatide producing significantly greater average weight loss than Wegovy at comparable maintenance doses. Individual results vary widely, and trial averages are not a promise of what any one person will experience.
FDA-Approved Uses
Zepbound is FDA-approved for two related purposes. First, for chronic weight management in adults with a body mass index (BMI) of 30 or greater (obesity), or 27 or greater (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea, as an adjunct to a reduced-calorie diet and increased physical activity. Second, as of December 2024, Zepbound is approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, again alongside a reduced-calorie diet and exercise – the first medication approved for this use. These are medical indications; Zepbound is not approved for cosmetic weight loss in people who do not meet the criteria.
How Zepbound Is Dosed (Prescriber-Directed)
Zepbound is given as a once-weekly subcutaneous injection, usually in the abdomen, thigh, or upper arm. Dosing is directed by your prescriber: treatment starts at a low dose and is increased gradually – generally no more than once every four weeks – based on how well you tolerate it and how you respond. This slow titration is intended to limit gastrointestinal side effects.
Do not adjust, skip ahead, or self-titrate your dose, and do not use another person’s medication or dose. Not everyone needs a maximum dose; many patients do well at intermediate doses. Your prescriber will determine the right dose and pace for you and monitor your response over time. For clinician-guided detail on how dose escalation typically works, see our Zepbound dose schedule guide and Zepbound dosing guide, and always follow the specific instructions you are given.
What to Expect in the First Six Months
Many patients notice appetite reduction within the first week or two, often described as feeling full faster and losing interest in high-calorie snacks. Meaningful weight loss typically appears within the first one to two months, accelerating through the titration period. On average, trial participants lost several percent of body weight in the first few months and 15 to 20 percent by roughly 40 to 52 weeks for those reaching higher doses.
Weight loss is not linear. Patients commonly experience two or three weeks of plateau followed by renewed progress, often tied to dose escalations. Full plateau and body-weight stabilization typically occur later in the first or second year for patients on maintenance therapy, though individual variation is substantial.
Common and Serious Side Effects
The most frequently reported Zepbound side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, indigestion, and abdominal pain. Nausea affected a substantial minority of patients on higher doses in SURMOUNT-1, typically during dose escalation. Most gastrointestinal side effects are mild to moderate and diminish over weeks to months as the body adjusts.
Less common but more serious potential side effects include pancreatitis (severe, persistent abdominal pain that may radiate to the back, with or without vomiting – seek care promptly), gallbladder disease, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), diabetic retinopathy complications, and severe allergic reactions. Rare reports of suicidal thoughts during GLP-1 treatment prompted the FDA to investigate, though large database studies have not confirmed a causal link. For complete side-effect information, see our tirzepatide side effects article, and report concerning symptoms to your clinician.
Who Should Not Take Zepbound
As noted in the boxed warning, people with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take Zepbound. It is also not recommended for people with active pancreatitis, severe gastrointestinal disease such as severe gastroparesis, or a known allergy to tirzepatide. Zepbound is not recommended during pregnancy, and people who could become pregnant should discuss contraception with their clinician (oral hormonal contraceptives may be less effective around dose changes). Your prescriber will review your complete medical history before prescribing.
What Happens When You Stop Zepbound
Real-world and trial data both show that weight regain is common when tirzepatide is discontinued. The SURMOUNT-4 trial studied this directly: participants who stopped tirzepatide regained a large share of the weight they had lost over the following year, while those who continued treatment maintained or further reduced their weight.
This mirrors what researchers have long understood about obesity as a chronic condition: stopping treatment tends to produce rebound, much as stopping blood-pressure medication can produce rebound hypertension. For patients considering a long-term plan, the data support continued therapy for most responders, but that decision belongs with you and your clinician.
Compounding Wind-Down and Counterfeit Caution
During the period when tirzepatide was in short supply, some compounding pharmacies made non-FDA-approved versions. The FDA has since declared the tirzepatide shortage resolved, and compounded tirzepatide is no longer permitted under the shortage-related allowances. That means the safe, legal source is FDA-approved Zepbound obtained through legitimate pharmacies.
The FDA has warned about counterfeit and unapproved products marketed as tirzepatide or “semaglutide/tirzepatide” online. These may contain the wrong ingredient, wrong dose, or contaminants and are potentially dangerous. Do not buy tirzepatide from unverified online sellers, social media, or med spas offering “compounded” or research-grade product; obtain it only with a valid prescription through a licensed pharmacy or a legitimate manufacturer channel.
Cost and Access
Zepbound’s list price has been reported near $1,060 per month, though a Lilly savings card can lower the out-of-pocket cost for many commercially insured patients, and Lilly’s self-pay LillyDirect program has offered single-dose vials at reduced cash prices for eligible patients without coverage. Prices, savings programs, and vial pricing change frequently, so verify the current figures with Eli Lilly and LillyDirect. Insurance coverage has been expanding but remains inconsistent – see our Zepbound cost without insurance guide and Zepbound price breakdown for details.
Frequently Asked Questions
How fast does Zepbound work for weight loss?
Many patients notice appetite reduction within the first one to two weeks, with measurable weight loss appearing within the first month or two. Trial data show progressive loss over the first year for patients who reach higher doses, but individual results vary.
How much weight can you lose on Zepbound?
In SURMOUNT-1, average weight loss at 72 weeks was about 22.5 percent on the highest dose studied. Individual results vary significantly – some people lose more, others less. Averages from a trial are not a guarantee of personal results.
Do you gain weight back after stopping Zepbound?
Most patients regain a significant portion of the lost weight after stopping, as shown in SURMOUNT-4. Obesity experts generally treat Zepbound as long-term therapy rather than a short-term cycle, but continuation is a decision to make with your clinician.
Is Zepbound better than Wegovy for weight loss?
Head-to-head data from SURMOUNT-5 showed tirzepatide (Zepbound) producing greater average weight loss than semaglutide (Wegovy) at comparable maintenance doses. Individual response varies, and side-effect profiles differ slightly between the drugs.
Who shouldn’t take Zepbound?
People with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome must not take Zepbound (boxed warning). It is also inappropriate for people with active pancreatitis, certain severe gastrointestinal conditions, a documented allergy to tirzepatide, and generally during pregnancy. Discuss your full history with your prescriber.
Is compounded tirzepatide a safe way to save money?
No. With the shortage resolved, compounded tirzepatide is no longer permitted, and the FDA has warned about counterfeit and unapproved products. Use only FDA-approved Zepbound obtained through a licensed pharmacy or legitimate manufacturer program.
The Bottom Line on Zepbound for Weight Loss
Zepbound has produced some of the largest average weight-loss outcomes of any FDA-approved obesity medication, and for many patients it represents a meaningful medical option short of surgery. It is a prescription treatment for a chronic disease – not a cosmetic product – and it carries real risks, including a thyroid boxed warning and the possibility of serious side effects. It works best as part of an ongoing plan that includes dietary changes, physical activity, and regular medical follow-up. Expect gradual, prescriber-directed titration, manageable side effects during dose escalation for most people, and weight loss that builds over the first year. Do not self-adjust your dose, avoid compounded or counterfeit versions, and work closely with your clinician to match treatment to your health, response, and tolerability.
Disclaimer: This article is general health information, not medical advice, and does not replace guidance from a licensed clinician. Zepbound (tirzepatide) is a prescription medication with a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Do not start, stop, or adjust any medication or dose on your own. Prices, coverage, and program terms change – verify current details with Eli Lilly, LillyDirect, and the FDA-approved prescribing information, and discuss your specific situation with your prescriber. If you have a medical emergency, call 911.
Sources
- FDA – Zepbound (tirzepatide) prescribing information, including the boxed warning for thyroid C-cell tumors and contraindications (MTC, MEN 2)
- FDA – approval for chronic weight management (2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024)
- FDA – statements on resolution of the tirzepatide shortage, the end of compounding allowances, and warnings about counterfeit/unapproved GLP-1 products
- MedlinePlus – tirzepatide (Mounjaro/Zepbound) drug information (warnings, indications, dosing, side effects)
- Eli Lilly – Zepbound product information and LillyDirect self-pay pricing (verify current figures)
- New England Journal of Medicine – SURMOUNT-1 (2022) and related SURMOUNT-2, SURMOUNT-4, and SURMOUNT-5 trial results